CervoMed (CRVO)
NASDAQ:CRVO
Want to see CRVO full AI Analyst Report?
CRVO Stock Chart & Stats
$3.98
-$0.11(-4.76%)
At close: 4:00 PM EST
$3.98
-$0.11(-4.76%)
Day’s Range― - ―
52-Week Range$2.13 - $13.13
Previous CloseN/A
Volume72.82K
Average Volume (3M)112.80K
Market Cap
$39.26M
Enterprise Value$27.33M
Total Cash (Recent Filing)$12.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Aug 17, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.27
Shares Outstanding9,258,719
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue84.74
Enterprise Value/Gross Profit84.74
Enterprise Value/Ebitda-0.91
Forecast
1Y Price Target
$20.40Price Target Upside412.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.7
Revenue Forecast (FY)$228.57K
Bulls Say, Bears Say
Bulls Say
Strengthened IP ProtectionA USPTO notice of allowance for neflamapimod in pure DLB creates multi-year exclusivity (protection into 2042), supporting a durable competitive moat in a disease area with no approved therapies. This strengthens licensing, partnership leverage, and long-term value capture if pivotal trials succeed.
Biomarker-driven Clinical ProgressRobust Phase 2b MRI and biomarker signals (basal forebrain volume preservation; greater benefit in low pTau181 patients) enable targeted, enrichment-based Phase 3 design and regulatory alignment. Structural biomarkers and dose-response insights reduce development risk and improve odds of a successful, efficient pivotal program.
Extended Financing Runway And Low LeverageRecent financings (~$10.5M private placement and additional registered offerings) alongside a zero-debt capital structure provide near-term funding to advance Phase 3 planning and mid-stage trials. Low leverage preserves flexibility for non-dilutive partnerships and strategic collaborations as clinical milestones progress.
Bears Say
Minimal And Declining RevenueCervoMed remains a pre-commercial biotech with negligible product-derived revenue and a pronounced decline year-over-year. Lack of recurring sales means long-term value depends entirely on clinical success and external funding rather than operating cash generation, increasing execution risk over the next 2–6 months.
High And Worsening Cash BurnSustained negative operating and free cash flow reflects heavy R&D and development spending. Persistent cash burn forces dependence on periodic equity raises or partnerships, constraining strategic optionality and making timely milestone execution contingent on securing future financing without guaranteed terms.
Eroding Equity And Shrinking AssetsMaterial declines in equity and total assets signal balance-sheet shrinkage as losses are funded by share issuance and cash drawdowns. This deterioration limits borrowing capacity, increases dilution risk for existing shareholders, and reduces cushion against unforeseen trial delays or cost overruns.
CervoMed News
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $2.13 and its highest was $13.13 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $39.26M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Aug 17, 2026 which is in 57 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on May 18, 2026. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.786 by -$0.074.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -0.8.
How many shares outstanding does CervoMed have?
CervoMed has 9,258,719 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.786. Following the earnings report the stock price went down -11.628%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.40 (412.56% Upside)
$20.40 (412.56% Upside)
Hedge Fund Trend
Decreased
By 74.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 17.0%
Last 30 Days ▲ 17.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.60%
12-Months-Change
Fundamentals
Return on Equity
-136.08%
Trailing 12-Months
Asset Growth
-60.82%
Trailing 12-Months
Company Description
CervoMed
CervoMed Inc., headquartered in Boston, Massachusetts, operates as a clinical-stage biotechnology firm committed to discovering, developing, and ultimately bringing to market pharmaceutical solutions for various neurodegenerative conditions. A central component of their therapeutic pipeline is neflamapimod, an innovative small molecule designed for oral administration and capable of crossing the blood-brain barrier. This compound is currently being advanced as a potential treatment for debilitating ailments such as Lewy body dementia (DLB), Alzheimer's disease, and for aiding recovery following a cerebral stroke.
CRVO Stock 12 Month Forecast
Average Price Target
$20.40
▲(412.56% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
54.37% Insiders
4.16% Mutual Funds
1.00% Other Institutional Investors
36.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---